Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study

Asian J Surg. 2023 Aug;46(8):3275-3277. doi: 10.1016/j.asjsur.2023.03.030. Epub 2023 Mar 23.

Authors

Tingting Tu¹, Yang Li¹, Ying Liu¹, Lifeng Jiang²

Affiliations

¹ Department of Integrated Traditional and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
² Department of Integrated Traditional and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China. Electronic address: [email protected].

PMID: 36964068
DOI: 10.1016/j.asjsur.2023.03.030

No abstract available

Keywords: EGFR mutations; Immune checkpoint inhibitors; Immunotherapy; Non-small cell lung cancer.

Publication types

Letter

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / therapy
ErbB Receptors / genetics
Humans
Immunotherapy
Lung Neoplasms* / genetics
Lung Neoplasms* / therapy
Retrospective Studies

Substances

ErbB Receptors
EGFR protein, human